Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

摘要: The introduction of biological agents targeting tumor necrosis factor-alpha (TNF-α) has brought about a paradigm shift in the treatment rheumatoid arthritis (RA). Although these anti-TNF have excellent efficacy against RA, substantial number patients still show inadequate responses. In Western countries, such are already being treated with new classes antirheumatic drugs as abatacept and rituximab. Tocilizumab (TCZ) is humanized monoclonal antibody developed Japan human interleukin-6 (IL-6) receptor. TCZ does not only alleviate signs symptoms RA but also seems to prevent progressive bone joint destruction. However, there concern that might increase risk adverse events infections since IL-6 plays pivotal role immune system. Calculating relative risks specific outcomes use remains difficult, due insufficient patient numbers enrolled clinical trials date. This review presents tentative guidelines for prepared by College Rheumatology based on results countries. intended guide postmarketing surveillance practice, will be revised periodically surveillance.